Journal article
Glucagon-Like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease: A Narrative Review
Gastro hep advances, v 5(9), 101023
01 Jan 2026
PMID: 42405289
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have progressed from the initial discovery of endogenous GLP-1 biology in 1986 to widely used therapies for type 2 diabetes and obesity, with expanding indications driven by pleiotropic metabolic and cardiovascular benefits. Although no randomized controlled trials have evaluated GLP-1RA as inflammatory bowel disease (IBD)-directed therapy, retrospective observational studies in IBD populations prescribed GLP-1RA for metabolic indications provide emerging real-world evidence regarding weight loss efficacy, IBD-related outcomes, and adverse events. This narrative review summarizes GLP-1RA pharmacology, mechanistic rationale, and the current clinical evidence base in IBD, with emphasis on safety considerations and priorities for prospective trials.
Metrics
1 Record Views
Details
- Title
- Glucagon-Like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease: A Narrative Review
- Creators
- Aakash Desai (Corresponding Author) - Allegheny Health NetworkHany Habib - Allegheny Health NetworkLina Wahbeh - Allegheny Health NetworkFrancis A. Farraye - Jacksonville College
- Publication Details
- Gastro hep advances, v 5(9), 101023
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- General Internal Medicine
- Web of Science ID
- WOS:001813212600001
- Scopus ID
- 2-s2.0-105043293789
- Other Identifier
- 991022199996904721